Methotrexate Update

References

• Alarcón G S, Tracy I C, Blackburn WD, Jr. Methotrexate in Rheumatoid Arthritis: Toxic Effects as the Major Factor in Limiting Long-Term Treatment. Arthritis Rheum 1989; 32: 671–6
   PubMed Web of Science ®Google Scholar
• Morgan S L, Baggott J E, Vaughn W H, Young PK., Austin J V, Krumdieck CL, et al. The Effect of Folic Acid Supplementation on Toxicity of Low-Dose Methotrexate in Patients With Rheumatoid Arthritis. Arthritis Rheum 1990; 33: 9–18
   PubMed Web of Science ®Google Scholar
• Morgan S L, Baggott J E, Vaughn W H, Austin J S, Veitch T A, Lee JY, et al. Supplementation With Folic Acid During Methotrexate Therapy for Rheumatoid Arthritis. A Double-Blind Placebo Controlled Trial. Ann Intern Med 1994; 121: 833–41
   PubMed Web of Science ®Google Scholar
• Joyce D A, Will R K, Hoffman D, Laing M. B, Blackbourn SJ. Exacerbation of Rheumatoid Arthritis in Patients Treated With Methotrexate After Administration of Folinic Acid. Ann Rheum Dis 1991; 50: 913–4
   PubMed Web of Science ®Google Scholar
• Tishler M, Caspi D, Fishel Yaron B. M. The Effects of Leucovorin (Folinic Acid) on Methotrexate Therapy in Rheumatoid Arthritis Patients. Arthritis Rheum 1988; 31: 906–8
   PubMed Web of Science ®Google Scholar
• Shiroky J B, Neville C, Esdaile J M, Choquette D, Zummer M, Hazeltine M, et al. Low-Dose Methotrexate With Leucovorin (Folinic Acid) in the Management of Rheumatoid Arthritis. Results of a Randomized, Double-Blind. Placebo-Controlled Trial. Arthritis Rheum 1993; 36: 795–803
   PubMed Web of Science ®Google Scholar
• Weinblatt M E, Maier A L, Coblyn JS. Low-Dose Leucovorin Does Not Interfere With the Efficacy of Methotrexate in Rheumatoid Arthritis: An 8 Week Randomized Placebo Controlled Trial. J. Rheumatol 1993; 20: 950–2
   PubMedGoogle Scholar
• Furst D E, Koehnke Burnmeister R. LF, et al. Increasing Methotrexate Effect With Increasing Dose in the Treatment of Resistant Rheumatoid Arthritis. J. Rheumatol 1989; 16: 313–20
   PubMed Web of Science ®Google Scholar
• Weinblatt M E, Coblyn J S, Fox D A, Holdsworth D E, Glass D N, Trentham DE. Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. N Engl J Med 1985; 312: 818–22
   PubMed Web of Science ®Google Scholar
• Williams J H, Willkins RF., Samuelson Co, Jr, Alarcon G S, Guttadauria M, Yarboro C, et al. Comparison of Low-Dose Oral Pulse Methotrexate and Placebo in the Treatment of Rheumatoid Arthritis: A Controlled Clinical Trial. Arthritis Rheum 1985; 28: 721–30
   PubMed Web of Science ®Google Scholar
• Andersen P A, West S G, O'Dell J R, Via C S, Claypool R G, Kotzin BL. Weekly Pulse Methotrexate in Rheumatoid Arthritis: Clinical and Immunologic Effects in a Randomized, Double-Blind Study. Ann Intern Med 1985; 103: 489–96
   PubMed Web of Science ®Google Scholar
• Furst D E, Erikson Clute N. L, Koehnke R, Burmeister L F, Kohler JA. Adverse Experience With Methotrexate During 176 Weeks of a Long-Term Prospective Trial in Patients With Rheumatoid Arthritis. J. Rheumatol 1990; 17: 1628–35
   PubMed Web of Science ®Google Scholar
• Weinblatt M E, Weissman B N, Holdsworth D E, Fraser P A, Maier A L, Falchuk KR., et al. Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis: 84-Month Update. Arthritis Rheum 1992; 35: 129–37
   PubMed Web of Science ®Google Scholar
• Kremer J M, Phelps CT. Long-Term Prospective Study of the Use of Methotrexate in the Treatment of Rheumatoid Arthritis: Update After a Mean of 90 Months. Arthritis Rheum 1992; 35: 138–45
   PubMed Web of Science ®Google Scholar
• Nyfors A. Líver Biopsies From Psoriatics Related to Methotrexate Therapy: 3. Findings in Post-Methotrexate Liver Biopsies From 160 Psoriatics. Acta Pathol Microbiol Scand [A] 1977; 85: 511–8
   PubMedGoogle Scholar
• Zachariae H, Kragballe K, Sogaard H. Methotrexate Induced Liver Cirrhosis Studies Including Serial Liver Biopsies During Continued Treatment. Brit J. Dermatol 1980; 102: 407–12
   PubMed Web of Science ®Google Scholar
• Weinstein G D, Reonigk H, Maibach H I, Weinstein G, Cosmides J, Halperin K., et al. Psoriasis-Liver-Methotrexate Interactions. Arch Dermatol 1973; 108: 36–42
   PubMedGoogle Scholar
• Walker A M, Funch D, Dreyer N A, Tolman K G, Kremer J M, Alarcón GS, et al. Determinants of Serious Liver Disease Among Patients Receiving Low-Dose Methotrexate for Rheumatoid Arthritis. Arthritis Rheum 1993; 36: 329–35
   PubMedGoogle Scholar
• Kremer L M, Lee R, Tolman G. KG. Liver Histology in Rheumatoid Arthritis Patients Receiving Long-Term Methotrexate Therapy: A Prospective Study With Baseline and Sequential Biopsy Samples. Arthritis Rheum 1989; 32: 121–7
   PubMed Web of Science ®Google Scholar
• Kremer J M, Kaye GI. Electron Microscopic Analysis of Sequential Liver Biopsy Samples From Patients With Rheumatoid Arthritis: Correlation With Light Microscopic Findings. Arthritis Rheum 1989; 32: 1202–13
   PubMedGoogle Scholar
• Kremer J M, Kaye G I, Kaye N W, Ishak K G, Axiotiz CA. Light and Electron Microscopic Analysis of Sequential Liver Biopsy Samples From Patients With Rheumatoid Arthritis Receiving Long-Term Methotrexate Therapy: Follow-Up Over prolonged Treatment Intervals and Correlation With Clinical and Laboratory Variables. Arthritis and Rheum 1995; 38: 1194–1203
   PubMedGoogle Scholar
• Kremer J M, Furst D, Weinblatt M E, Blotter SD. Significant Changes in Serum AST Across Hepatic Histological Biopsy Grades: An Analysis of 3 Prospective Cohorts on Methotrexate Therapy for Rheumatoid Arthritis. J. Rheum 1996; 23: 459–61
   PubMed Web of Science ®Google Scholar
• Kremer J M, Alarcon G S, Lightfoot R W, Wilkens R F, Furst D E, Williams HJ, et al. Methotrexate for Rheumatoid Arthritis: Suggested Guidelines for Monitoring Liver Toxicity. Arthritis and Rheum 1994; 37(3)316–28
   PubMedGoogle Scholar
• Roenigk HH, Jr, Auerbach R, Maibach H I, Weinstein GD. Methotrexate in Psoriasis: Revised Guidelines. J Am Acad Dermatol 1988; 19: 145–56
   PubMed Web of Science ®Google Scholar
• Kremer J M, Alarcon G S, Alexander R W, Cannon GW, et al. Methotrexate (MTX) Lung Toxicity: Clinical Features of Thirty-Seven Cases From Seven Rheumatology Practices. Arthritis Rheum 1995; 37: s205
   Google Scholar
• Kremer J M, Petrillo G F, Hamilton RA. Pharmacokinetics and Renal Function in Patients With Rheumatoid Arthritis Receiving a Standard Dose of Oral Weekly Methotrexate Over a Period of 24 Months: Association With Significant Decreases in Creatinine Clearance and Renal Clearance of the Drug. J. Rheumatol 1995; 22: 38–40
   PubMed Web of Science ®Google Scholar
• Kremer J M, Petrillo G F, Hamilton RA. The Effects of Nonsteroidal Anti-Inflammatory Drugs on Methotrexate Pharmacokinetics: Impairment of Renal Clearance of MTX at Weekly Maintenance Doses but not at 7.5 mg. J. Rheum 1995; 22: 2072–7
   PubMed Web of Science ®Google Scholar
• Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis. N Engl J Med 1995; 333: 137–41
   PubMed Web of Science ®Google Scholar
• O'Dell J R, Haire C E, Erikson N, Drymalski W, Palmer W, Eckhoff J, et al. Treatment of Rheumatoid Arthritis With Methotrexate Alone, Sulfasalazine and Hydrochloroquine or a Combination of All Three Medications. N Engl J Med 1996; 334: 1287–91
   PubMed Web of Science ®Google Scholar
• Hamilton R A, Kremer JM. Why Intramuscular Methotrexate May be More Efficacious Than Oral Dosing in Patients With Rheumatoid Arthritis. Brit J Rheum 1996, in press
   PubMedGoogle Scholar
• Kremer JM. The Mechanism of Action of Methotrexate in Rheumatoid Arthritis: The Search Continues. J. Rheumatol 1994; 21: 1–5
   PubMedGoogle Scholar